Biotech

The Gold No-Brainer | 5/26/2020

… because its success or failure relies on a quirky combination of monetary trends and mob psychology. The metal doesn’t produce products or earnings. It will never design a new iPhone app or a revolutionary biotech drug. It just sits there like a diva, basking in adoration from its fans. That said, gold occasionally offers great, if not spectacular, trading opportunities. I will go out on a limb — way out — to …

Novavax starts Phase 1 clinical trial of coronavirus vaccine candidate | Yahoo News | 5/26/2020

Reuters) - U.S. biotech group Novavax Inc has joined the race to test coronavirus vaccine candidates on humans and enrolled its first participants on Monday. Novavax, shares in which surge about 23% to $56.50 in premarket trade, said it expects preliminary readings on safety and on indicators of an immune response from the trial in July. The announcement comes as drugmakers pause clinical trials on drugs for other ailments to focus …

Follow Biotech:    

Avison Young Completes Sale of Biotech Research Facility in Florida’s Gainesville Market | 5/26/2020

Avison Young Completes Sale of Biotech Research Facility in Florida’s Gainesville Market Avison Young Completes Sale of Biotech Research Facility in Florida’s Gainesville Market 1031 exchange deal one of the largest single office transactions in Alachua County Gainesville, Fla. — Avison Young closed the $12 million sale of a biotech and life science research facility in Foundation Park, located at 14193 NW 119 th Terrace in Alachua, Florida. The newly constructed …

Sanofi to slash $12bn stake in biotech Regeneron - One News Page | 5/26/2020

CEO Paul Hudson says proceeds will go to scientific research and potentially acquisitions …

France’s Sanofi to sell stake in Regeneron | 5/26/2020

France’s Sanofi to sell stake in Regeneron By AFP French pharmaceutical giant Sanofi on Monday said it planned to divest its stake in US biotech firm Regeneron which is valued at around $13 billion. Sanofi, which holds around 20.6 percent in Regeneron, however insisted it had no intention of halting its partnership with the American firm. The sale will see a repurchase by Regeneron of $5 billion of its stock …

Australian Market Extends Gains | Markets Insider | Business Insider | 5/26/2020

RTTNews) - The Australian stock market is extending gains on Tuesday from the previous session amid optimism about a recovery in global economic growth as lockdown restrictions are eased in the country and other parts of the world such as Japan and Spain. News that U.S. biotech firm Novavax has commenced the first human trial of its experimental coronavirus vaccine also boosted sentiment. The benchmark S&P/ASX 200 Index is …

Japanese Market Notably Higher | Markets Insider | Business Insider | 5/26/2020

… fresh cues from Wall Street, which was closed overnight for a holiday. Investor sentiment was boosted after the Japanese government on Monday lifted a nationwide state of emergency over the coronarivus. News that U.S. biotech firm Novavax has commenced the first human trial of its experimental coronavirus vaccine also boosted sentiment. The benchmark Nikkei 225 Index is adding 392.92 points or 1.89 percent to 21,134.57, after touching a high of …

StockTwits Trending Alert: Trading recent interest in SPDR S&P BIOTECH $XBI | 5/26/2020

Quantcha now offering unlimited commission-free options trading . Quantchabot has detected a promising Bull Call Spread trade opportunity for SPDR S&P BIOTECH ( XBI ) for the 5- XBI was recently trading at $106.05 and has an implied volatility of 39.91% for this period. Based on an analysis of the options available for XBI expiring on 5-Jun-2020, there is a 34.17% likelihood that the underlying will close within the …

7 “Bright Spot” Biotech Stocks In The Spotlight | 5/26/2020

David Goldstein On the Radar Reports , Zenect Wealth “With the scramble for viral and antibody testing kits, and the ultimate goal of finding a vaccine for Covid-19, many biotech companies are suddenly in the spotlight. Even those that aren’t directly working on a Covid-related solution look more attractive,” observes the author of today’s article, who also singles out biotech stocks as being the one possible bright spot in …

Daxor (NYSEAMERICAN:DXR) Downgraded by Zacks Investment Research | 5/26/2020

Daxor (NYSEAMERICAN:DXR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks.com reports. According to Zacks, “Daxor Corporation is a medical device manufacturing corporation with additional biotech services. “ Get Daxor alerts: Shares of DXR traded up $0.54 during midday trading on Monday, hitting $14.04. 900 shares of the stock were exchanged, compared to …

Patients’ interest first, profit next | 5/26/2020

… this medicine. Remdesivir is not a new molecule but originally developed to combat Ebola. It was tested against Ebola outbreak in the Democratic Republic of the Congo but showed no effect. The innovator American Biotech Company, Gilead Sciences, did not lose hope and pursued its research. Now, clinical trials are on globally. Notably, it’s not Gilead alone that developed this drug and brought this molecule up to this stage. This …

‘Human trials for COVID-19 vaccine may begin in at least 6 months’ (IANS Exclusive) | 5/26/2020

… Research (ICMR) said, “The virus strain isolated at the National Institute of Virology (NIV) laboratory in Pune will be used to develop the vaccine, and this strain has been successfully transferred to the Bharat Biotech International Ltd.(BBIL). It is expected that the human trials of the vaccine will begin in at least six months.”Queried on the focus areas as India inches closer to 1.4 lakh COVID-19 cases …

India to Begin Human Trials of COVID-19 Vaccine in Six Months | The Weather Channel | 5/26/2020

The virus strain isolated at the National Institute of Virology (NIV) laboratory in Pune will be used to develop the vaccine, and this strain has been successfully transferred to the Bharat Biotech International Ltd. (BBIL). It is expected that the human trials of the vaccine will begin in at least six months.” Queried on the focus areas as India inches closer to 1.4 lakh COVID-19 cases, Kant said we …

Facility Maintenance Technician | 5/26/2020

Biotech Company in Eatonton seeking Facility Maintenance Technician:Duties:Responsible for all aspects of building: doors, floors, windows and lighting, cooling towers, pumps and motors, boiler/Autoclave, refrigeration systems, temperature controlled environments, and miscellaneous laboratory equipment.Minimum Requirements:High school diploma or equivalent, Trade school courses preferred1-3 years experience in general maintenancePreferred Qualifications:Ability to troubleshoot and repair most mechanical systems3-5 years working experience in biomedical fieldHVAC experiencePlease send resume to …

mRNA vaccines, a primer: How they work, why they’re “cleaner” than traditional vaccines, and why they might prove catastrophic in a rushed coronavirus response | 5/26/2020

mRNA vaccines, a primer: How they work, why they’re “cleaner” than traditional vaccines, and why they might prove catastrophic in a rushed coronavirus response Monday, May 25, 2020 by: Mike Adams Tags: antigens , biochemistry , biotech , biotech nology , coronavirus , covid-19 , DNA , genetic engineering , genetics , goodhealth , goodmedicine , goodscience , Moderna , mRNA , RNA , vaccines ( Natural News ) mRNA vaccines — also called “genetic vaccines”— arise from an innovative biotech nology approach that turns the body’s cells into …

US biotech firm Novavax begins Covid-19 vaccine trials on Australian volunteers after getting $388mn from Bill Gates-backed fund | 5/26/2020

… bless those that agree to participate in this trial run when the time comes.I wish them well. https://t.co/OPxsrc0Ujd — Musicaljane ⭐️⭐️⭐️ (@musicaljane1) May 25, 2020 Novavax is not the first US biotech firm to launch clinical trials for a coronavirus inoculation, however, with Massachusetts’ Moderna rolling out human testing in March and reporting positive results – to which internet sleuths have yet to discover any ‘damning ties.’ At …

97106122_665471707641688_469051926697213952_o | Labland Biotechs | Flickr | 5/26/2020

Explore lablandbiotechs’ photos on Flickr. lablandbiotechs has uploaded 2 photos to Flickr …

FTR #1131 Bio-Psy-Op Apocalypse Now, Part 7: Moderna Uber Alles | 5/26/2020

… Chiefs of Staff, Gen­er­al Mark A. Mil­ley) are of addi­tion­al con­cern. As of 2016, Mod­er­na had the largest val­u­a­tion of any pri­vate biotech firm and for­mer employ­ees felt that Mod­er­na prized mon­ey over sci­ence. Note that, as will be reviewed lat­er in the pro­gram, its stock has risen expo­nen …

Aduro BioTech Inc Forecasted to Post FY2020 Earnings of ($0.63) Per Share (NASDAQ:ADRO) | 5/25/2020

Aduro BioTech Inc (NASDAQ:ADRO) – Equities researchers at SVB Leerink dropped their FY2020 EPS estimates for Aduro BioTech in a note issued to investors on Wednesday, May 20th. SVB Leerink analyst D. Graybosch now expects that the biotechnology company will post earnings per share of ($0.63) for the year, down from their previous forecast of ($0.58). SVB Leerink has a “Outperform” rating and a $7.00 price objective on the stock …

EverQuote (EVER) : 2-year performance | 5/25/2020

… month performance 9-year performance ABBV Abengoa Yield (ABY) ABT AC-TBD Acceleron Pharma (XLRN) Adam Street Partners Adaptimmune Therapeutics (ADAP) ADCT Adeptus Health (ADPT) ADIL Admeld ADNT ADPT ADS Tactical (ADSI) ADT Aduro BioTech (ADRO) Advanced Drainage Systems (WMS) Aerie Pharmaceuticals (AERI) Aerohive Networks (HIVE) AFH AFYA Agile Therapeutics (AGRX) Agios (AGIO) Agricultural Bank of China AHI AI IPO AIH AIRB AKAO AKBA Akcea AKRO Alarm.com (ALRM) Albertsons Alcobra …

German regulators approve trial of French group Abivax’s coronavirus product | 5/25/2020

German regulators approve trial of French group Abivax’s coronavirus product / WTHI HI-99 May 25, 2020 01:24 am PARIS (Reuters) - French biotech group Abivax said on Monday German regulators had approved a trial to test its ‘ABX464’ product to help COVID-19 patients, following earlier French regulatory approval. Abivax said it received funding of 36 million euros ($39.20 million) from French state bank BPIfrance for the product, and added it …

Zacks: Analysts Anticipate Aduro BioTech Inc (NASDAQ:ADRO) to Post -$0.18 Earnings Per Share - TheOlympiaReport | 5/25/2020

Analysts expect Aduro BioTech Inc (NASDAQ:ADRO) to announce ($0.18) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Aduro BioTech’s earnings, with estimates ranging from ($0.24) to ($0.09). Aduro BioTech posted earnings of ($0.23) per share in the same quarter last year, which suggests a positive year over year growth rate of 21.7%. The company is scheduled to report its …

German Regulators Approve Trial of French Group Abivax’s Coronavirus Product | U.S. News & World Report | 5/25/2020

German Regulators Approve Trial of French Group Abivax’s Coronavirus Product By Reuters , Wire Service Content May 25, 2020 By Reuters , Wire Service Content May 25, 2020, at 1:22 a.m. More PARIS (Reuters) - French biotech group Abivax said on Monday German regulators had approved a trial to test its ‘ABX464’ product to help COVID-19 patients, following earlier French regulatory approval. Abivax said it received funding of 36 million euros ($39.20 …

Coronavirus map LIVE: Rishi Sunak formulates bold bailout plan to save UK companies | 5/25/2020

… on Monday it has started the Phase 1 clinical trial of a novel coronavirus vaccine candidate and has enrolled the trial’s first participants, with preliminary results slated for July. The Maryland-based late-stage biotech nology company in April said it identified the candidate, NVX-CoV2373, with which it planned to use its Matrix-M adjuvant to enhance immune responses. Adjuvants are mainly used to make vaccines induce a strong immune …

Fermenters Market : Upcoming Trends, Incredible Possibilities, Business Opportunities and Regional Outlook | 5/25/2020

… about 8.6 % during a forecast. Global fermenter market is segmented by application by the process and by region. Based on process fermenter market is segmented into single use and multiple uses. Food & Beverage, Pharmaceutical, Biotech nology, and others are application segments of fermenter market. Geographically fermenter market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. Request for Report sample : https://www.trendsmarketresearch.com/report/sample/11076 The …

Food and Drug Administration

Immunomedics Gets Double-Downgrade to Sell From Goldman Sachs - TheStreet | 4/3/2020

… received a double downgrade to sell from buy from an analyst at Goldman Sachs, who cited a report by the Food and Drug Administration that found new quality control issues at the biopharm company&apos … 2000, which is down 38%, and the SPDR S&P Biotech ETF (XBI) which is down 21%. The FDA is expected to make a decision on sacituzumab govitecan as a third line of therapy in …

CAR-T

J&J inks Fate deal to move into allogeneic CAR therapies | FierceBiotech | 4/3/2020

… Raysonho/CC0) Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies. The deal, which features $3 billion in milestones, tasks Fate with … the CAR-T space by picking up rights to Legend Biotech’s anti-BCMA candidate, known within the Big Pharma as JNJ-4528. Having achieved a 69% complete response rate in a phase 1b/2 multiple …

COVID-19

GSK allies with Innovax for COVID-19 vaccine R&D project | FierceBiotech | 4/3/2020

GSK allies with Innovax for COVID-19 vaccine R&D project by Apr 3, 2020 9:05am One of GSK’s partners has early evidence an adjuvant works with COVID-19 vaccines. (GlaxoSmithKline) GlaxoSmithKline has teamed up with Xiamen Innovax Biotech to evaluate a vaccine against the novel coronavirus behind the COVID-19 pandemic. The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant …

Clinical Research

GENFIT adapts its activities to the coronavirus | Yahoo News | 3/31/2020

… coronavirus on its activities. First, the Phase 3 clinical trial in Nash (non-alcoholic steatohepatitis) with “Resolve-It” fibrosis continues. Biotech awaits comments from the FDA, and their integration for the continuation of the study … diagnostic solution continues to be deployed in the area of ​​clinical research. Despite a very marked interest in NIS4, the use of the test could be slowed down due to the delays potentially encountered by …

NIH

STAT Plus: AC Immune bets that its Alzheimer’s trial design could provide a cleaner test of the amyloid hypothesis | 3/30/2020

Biotech AC Immune bets that its Alzheimer’s trial design could provide a cleaner test of the amyloid hypothesis By Damian Garde @damiangarde , Rebecca Robbins @rebeccadrobbins , and Adam Feuerstein @adamfeuerstein March 30, 2020 National Institute on Aging, NIH T he fate of aducanumab , a potential Alzheimer’s treatment from Biogen, is widely seen as the last hope for an aging idea: that targeting toxic brain plaques can arrest the progress of the …

Precision Medicine

OneThree Biotech Announces $2.5M Seed Funding & Free Toxicity Screening for Small Molecules Treating COVID-19 | PR Newswire | 3/26/2020

OneThree Biotech Announces $2.5M Seed Funding & Free Toxicity Screening for Small Molecules Treating COVID-19 Biology-Driven AI-powered drug discovery and development platform backed by Primary Venture Partners and Meridian Street Capital News provided … Ph.D., Director of the Caryl and Israel Englander Institute for Precision Medicine, Associate Director of the Institute for Computational Biomedicine, and Co-Director of the WorldQuant Initiative for Quantitative Prediction at Weill Cornell Medicine. Since …

Coronavirus

Plan to boost coronavirus test numbers with delivery of kits by post | The Telegraph | 3/21/2020

Biotech companies are racing to respond to a call to boost the supply of coronavirus tests and facilities, as officials explore plans to send kits out to homes. A Cabinet Office memo to the industry has asked for “large scale testing services”, turnaround timetables and information on whether testing kits could be sent to individuals through the post. The request came as ministers laid out plans to increase the number …

Department of Health and Human Services

Mesa Biotech to Receive Funding from US Health and Human Services for Development of a 30 minute Molecular (PCR) Point-of-Care SARS-CoV-2 Test | PR Newswire | 3/19/2020

Sverige Mesa Biotech to Receive Funding from US Health and Human Services for Development of a 30 minute Molecular (PCR) Point-of-Care SARS-CoV-2 Test Since its inception at Los Alamos National Lab … it has been awarded a $561K contract from the US Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA) for development of its rapid molecular diagnostic test for detection of …

Digital Health

Vivante Health Announces Collaboration with Janssen for Predictive Disease Modeling | PR Newswire | 3/17/2020

… Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop digital predictive biomarkers for chronic diseases. The agreement was facilitated by Johnson & Johnson Innovation LLC. The massive amount of information obtained through traditional electronic health data and, more recently, through digital health devices such as health apps is the driving force behind digital biomarkers. A growing field of study, digital biomarkers can explain, predict or influence health …

Regenerative Medicine

Fortress Biotech Reports Record Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Highlights Nasdaq:FBIO | Globe Newswire | 3/16/2020

… treatment of Menkes disease is on track to begin in the fourth quarter of 2020 NEW YORK, March 16, Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced financial results and recent … vaccines to date. In August 2019, MB-107 was granted Regenerative Medicine Advanced Therapy (“RMAT”) designation by the FDA. Also in August 2019, we entered into a license agreement with CSL Behring for the Cytegrity …

National Institutes of Health

Factbox: Global efforts to develop vaccines, drugs to fight the coronavirus | MSN | 2/20/2020

National Institutes of Health has started work using a platform developed by U.S. biotech Moderna Inc. Scientists at the University of Queensland in Australia and Inovio Pharmaceuticals Inc are using a different platform. The work is backed by grants from global health emergency group the Coalition for Epidemic Preparedness Innovations (CEPI). Novavax Inc, which said it created a vaccine candidate for Ebola within 90 days of the release of the …

Medicaid

Novartis gene therapy for fatal childhood disease delivers strong sales during fourth quarter | STAT | 1/29/2020

… Medicaid. advertisement Later this quarter, European regulators are expected to issue an approval decision for Zolgensma. In Japan, a similar decision is expected before the middle of the year, Novartis said. Related: Biotech earnings preview: Unsettled investors hoping for strong 2020 outlooks Zolgensma is currently approved to treat infants and children under the age of 2. An effort to treat older SMA children with a higher dose of Zolgensma remains …

National Institute of Allergy and Infectious Diseases

Several Drugmakers are Racing to Create and Test a Vaccine for China’s Deadly Coronavirus | PR Newswire | 1/29/2020

National Institute of Allergy and Infectious Diseases report that there are reasons why the drugmakers may have an advantage to quickly develop a vaccine for this infection. A broad group of biotech companies are hot on the trail of therapies that could be applied to the treatment of coronavirus. Some have been requested to move on the development at the request of agencies, while others are independently looking at how …

Gene Therapy

Akron Biotech CEO to Launch Children’s Book at Frost Science’s Future of Medicine Day | PR Newswire | 1/16/2020

MIAMI Scientist, business leader and innovator, Dr. Claudia Zylberberg , CEO of Akron Biotech in Boca Raton , will launch an updated version of her children’s book, You’re Full of Genes , during the Future of Medicine Day … as a labor of love, but as the cell and gene therapy industry propels forward at an unprecedented rate, I’ve found it is necessary to help educate the public, beginning with our youth,” Zylberberg said …

J.P. Morgan Healthcare Conference

Diverse Biotech Announces Its Seed Showcase Presentation at Biotech Showcase in San Francisco | PR Newswire | 1/16/2020

Diverse Biotech Announces Its Seed Showcase Presentation at Biotech Showcase in San Francisco News provided by Jan 15, 2020, 17:17 ET Share this article DOYLESTOWN, Pa. , Jan. 15, 2020 /PRNewswire/ – Diverse Biotech, Inc. www.diversebiotech.com has announced it was preferentially selected to make a presentation at 3pm Pacific Time today at the Biotech Showcase in San Francisco , which is a key Healthcare conference running in parallel to the JP Morgan Healthcare …

CRISPR

Regeneron’s Yancopoulos is bitter over Praluent. Can Novartis do better? | STAT | 1/15/2020

Biotech Regeneron’s Yancopoulos is still bitter over Praluent sales. Can Novartis do better? By Adam Feuerstein @adamfeuerstein January 15, 2020 Kristoffer Tripplaar/Sipa via AP S AN FRANCISCO — George Yancopoulos, Regeneron Pharma’s top scientist, is … interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. GET STARTED …

Virtual Care

VirTrial Wins Digital Health Solutions Category in the Fierce Innovation Awards – Life Sciences Edition 2019 | PRWeb | 1/9/2020

… VirTrial Wins Digital Health Solutions Category in the Fierce Innovation Awards – Life Sciences Edition 2019 Share Article VirTrial’s industry leading Virtual Care Management (VCM) program, which combines video, text, and email, is a new breed … Edition, a peer reviewed awards program from the publisher of FierceBiotech and FiercePharma. The competition highlights companies that demonstrated innovative solutions, technologies, and services that have the potential to make the greatest impact for biotech

Digital Health Solutions

VirTrial Wins Digital Health Solutions Category in the Fierce Innovation Awards – Life Sciences Edition 2019 | PRWeb | 1/9/2020

VirTrial Wins Digital Health Solutions Category in the Fierce Innovation Awards – Life Sciences Edition 2019 Share Article VirTrial’s industry leading Virtual Care Management (VCM) program, which combines video, text, and email, is a new breed … Edition, a peer reviewed awards program from the publisher of FierceBiotech and FiercePharma. The competition highlights companies that demonstrated innovative solutions, technologies, and services that have the potential to make the greatest impact for biotech

Genomics

ABCT, Connecticut’s Newest Accelerator Program for Biosciences Ventures, Announces 2020 Cohort of Life Science Startups | PRWeb | 1/6/2020

… their capacity to revolutionize the life sciences industry. The 2020 ABCT cohort participants and ventures include: Abhijit Patel (Yale): Binary Genomics aims to develop and commercialize a blood test to enable early cancer detection via … genetic challenges affecting the skeletal system. Elizabeth Cusack (Independent): RBK Biotech has developed a nutritional product optimized for cancer care aimed at preventing and alleviating cancer related nutritional crisis and metabolically rooted treatment side effects …

Clinical Collaboration

Portage Announces Filing of Financial Statements and Accompanying MD&A and Provides Company Operations Updates | PR Newswire | 12/31/2019

… presentation of Phase I/II data, and entry into a research collaboration with Merck – TORONTO , Dec. 31, 2019 /PRNewswire/ - Portage Biotech Inc., (“Portage” or the “Company”) (Canadian Securities Exchange: PBT.U, OTC Markets: PTGEF ) is very … in June, Portage announced that Intensity Therapeutics entered into a clinical collaboration with Merck to evaluate INT230-6, Intensity’s investigational treatment for refractory solid tumors, in combination with KEYTRUDA ® (pembrolizumab). Further clinical updates was presented at …

Big Pharma

The debate over America’s drug-pricing system is built on myths | STAT | 12/23/2019

There are several fundamental flaws in the argument that academia or Government bodies can develop new medicines and compete with or replace Big Pharma and Biotech. First, the Regulatory landscape has changed beyond all recognition since the 1960’s/70’s, making it much more expensive to develop a new medicine in order to meet standards that are rightly rigorous. Academia is simply not capable of developing drugs to Global …

Medicare

There’s more upside for biotech even after 24% gains in two months - MarketWatch | 12/12/2019

Biotech has been a great performer since I suggested it as a contrarian play on Oct. 11. In that time, the SPDR S&P Biotech exchange-traded fund XBI, +0.58% is up 24%, and the … analyst Michael Yee. “It doesn’t seem like drug pricing or Medicare for All are going to be in the near-term picture. If that’s the case, people feel better about biotech, and the stocks move …

Telehealth

Sanofi to restructure its Onduo, Verily partnership alongside diabetes exit | FierceBiotech | 12/10/2019

… Paul Hudson says they “over-invested”… will remain an investor but will no longer be involved operationally. pic.twitter.com/3FhndN3mb6 — Andy Biotech (@AndyBiotech) December 10, 2019 Regarding Onduo, Hudson said the company “over-invested” in the … starting HbA1c saw decreases of 2.3 percentage points through the telehealth program—from an average of 10.7% down to 8.3%. The data was taken from users from 21 U.S. states, with 30% living in rural …

Medical Research

Rat Model Market revenue to hit $1.8 billion by 2025: Global Market Insights, Inc. | Globe Newswire | 12/5/2019

… register around 8% CAGR up to 2025, impelled by increase in the number of research and development activities in pharma/biotech companies. December 05, 2019 05: Global Rat Model Market value is set to surpass … one of the animals that are widely used in the medical research since they are the primary model for mechanistic studies of human reproduction. Hence, all these factors are expected to boost the adoption of …

Advanced Analytics

Clarivate Analytics expands global life science alliances program with three new technology partners – Company Announcement - FT.com | Financial Times | 12/5/2019

… of sources are harmonized within a single unified platform, making it the industry’s richest resource for data-driven insights and advanced analytics. Cortellis intelligence spans the entire R&D lifecycle and includes 2 million+ molecular … commercialization. By supporting data-driven decisions, Cortellis helps pharmaceutical companies, biotech and medical device/diagnostic firms accelerate innovation. For more information, please visit clarivate.com/cortellis. About Clarivate Analytics Clarivate Analytics™ is a global leader in …

Janssen Biotech

Hematology/Oncology (Cancer) Approvals & Safety Notifications | FDA | 5/13/2020

… Janssen Biotech, Inc.) for adult patients with newly diagnosed or relapsed/refractory multiple myeloma. This new product allows for subcutaneous dosing of daratumumab. More Information . May 1, 2020 Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. More Information . April …

Moleculin Biotech

Moleculin Biotech (NASDAQ:MBRX) Earns Buy Rating from Analysts at Maxim Group | Daily Political | 4/12/2020

Maxim Group began coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research note released on Thursday, Stock Target Advisor reports. The firm issued a buy rating and a $3.00 target price on the stock.A number of other research firms have also recently weighed in on MBRX. Zacks Investment Research upgraded Moleculin Biotech from a hold rating to a strong-buy rating and set a $0.75 price target for …

Novartis

COVID-19 is bad news for new drug launches. Which will suffer most? | FiercePharma | 4/3/2020

… Novartis’ repurposed ofatumumab might also come late, ODDO BHF analysts noted recently. Register for the On-Demand Webinar Rollouts from small-cap biotechs with little to no marketing experience are likely most vulnerable, however. So are new meds challenging existing drugs—like Zeposia—chronic disease therapies and those that need heavy up-front awareness promotions, industry watchers figure. On the flipside, drugs for life-threatening diseases with few other options …

Celgene

COVID-19 is bad news for new drug launches. Which will suffer most? | FiercePharma | 4/3/2020

… ofatumumab might also come late, ODDO BHF analysts noted recently. Register for the On-Demand Webinar Rollouts from small-cap biotechs with little to no marketing experience are likely most vulnerable, however. So are new … report. RELATED: Bristol Myers nabs long-sought FDA nod for Celgene’s MS drug ozanimod, but pandemic delays launch As for Biogen, the Big Biotech is grappling with the coronavirus from within as several members of …

GSK

GSK allies with Innovax for COVID-19 vaccine R&D project | FierceBiotech | 4/3/2020

GSK allies with Innovax for COVID-19 vaccine R&D project by Apr 3, 2020 9:05am One of GSK’s partners has early evidence an adjuvant works with COVID-19 vaccines. (GlaxoSmithKline) GlaxoSmithKline has teamed up with Xiamen Innovax Biotech to evaluate a vaccine against the novel coronavirus behind the COVID-19 pandemic. The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant …

AbbVie

COVID-19 is bad news for new drug launches. Which will suffer most? | FiercePharma | 4/3/2020

… ofatumumab might also come late, ODDO BHF analysts noted recently. Register for the On-Demand Webinar Rollouts from small-cap biotechs with little to no marketing experience are likely most vulnerable, however. So are new … place Gilead Sciences and Galapagos’ JAK inhibitor filgotinib farther behind AbbVie’s Rinvoq in rheumatoid arthritis, RBC Capital analyst Brian Abrahams noted in a recent report. RELATED: Bristol Myers nabs long-sought FDA nod for Celgene’s …

Biogen

COVID-19 is bad news for new drug launches. Which will suffer most? | FiercePharma | 4/3/2020

… ofatumumab might also come late, ODDO BHF analysts noted recently. Register for the On-Demand Webinar Rollouts from small-cap biotechs with little to no marketing experience are likely most vulnerable, however. So are new … pressure, given there are already Novartis’ gene therapy Zolgensma and Biogen’s tried-and-true oral Spinraza on the market. Potential inspection, approval and launch delays will place Gilead Sciences and Galapagos’ JAK inhibitor filgotinib farther …

GlaxoSmithKline

GSK allies with Innovax for COVID-19 vaccine R&D project | FierceBiotech | 4/3/2020

GSK allies with Innovax for COVID-19 vaccine R&D project by Apr 3, 2020 9:05am One of GSK’s partners has early evidence an adjuvant works with COVID-19 vaccines. (GlaxoSmithKline) GlaxoSmithKline has teamed up with Xiamen Innovax Biotech to evaluate a vaccine against the novel coronavirus behind the COVID-19 pandemic. The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant …

Gilead Sciences

COVID-19 is bad news for new drug launches. Which will suffer most? | FiercePharma | 4/3/2020

… ofatumumab might also come late, ODDO BHF analysts noted recently. Register for the On-Demand Webinar Rollouts from small-cap biotechs with little to no marketing experience are likely most vulnerable, however. So are new … the market. Potential inspection, approval and launch delays will place Gilead Sciences and Galapagos’ JAK inhibitor filgotinib farther behind AbbVie’s Rinvoq in rheumatoid arthritis, RBC Capital analyst Brian Abrahams noted in a recent report. RELATED …

Gilead

COVID-19 is bad news for new drug launches. Which will suffer most? | FiercePharma | 4/3/2020

… ofatumumab might also come late, ODDO BHF analysts noted recently. Register for the On-Demand Webinar Rollouts from small-cap biotechs with little to no marketing experience are likely most vulnerable, however. So are new … the market. Potential inspection, approval and launch delays will place Gilead Sciences and Galapagos’ JAK inhibitor filgotinib farther behind AbbVie’s Rinvoq in rheumatoid arthritis, RBC Capital analyst Brian Abrahams noted in a recent report. RELATED …

Johnson & Johnson

J&J inks Fate deal to move into allogeneic CAR therapies | FierceBiotech | 4/3/2020

J&J inks Fate deal to move into allogeneic CAR therapies by Nick Paul Taylor Apr 3, 2020 8:40am Johnson & Johnson committed to up to $3 billion in milestones to land a deal with Fate … the CAR-T space by picking up rights to Legend Biotech’s anti-BCMA candidate, known within the Big Pharma as JNJ-4528. Having achieved a 69% complete response rate in a phase 1b/2 multiple …

Bristol-Myers Squibb

BMS, bluebird file for approval of CAR-T cell therapy for multiple myeloma - MedCity News | 4/1/2020

Drugmaker Bristol-Myers Squibb and a biotech company with which it has partnered have sent their application to the Food and Drug Administration seeking approval for what could become the first approved CAR-T cell therapy to treat the second most common form of blood cancer. New York-based BMS and Cambridge, Massachusetts-based bluebird bio said Tuesday that they had filed for approval of idecabtagene vicleucel, also known as …

Thermo Fisher

The Global Bioremediation Market report projects the market to grow at a significant CAGR of 7.72% during the forecast period from 2019 to 2028 | Globe Newswire | 4/1/2020

Thermo Fisher Scientific Inc., Drylet, LLC, Microgen Biotech Ltd., Organic Biotech Pvt. Ltd. and Probiosphere? • Which component type is expected to dominate the market in 2028? • Which medium type is expected to dominate the market in 2028? • Which application type is expected to dominate the market in 2028? • Which region dominated the global bioremediation market in 2018 and what are the expected trends from each of the regions in the …

Abbott Laboratories

Med-tech front lines against COVID-19 includes array of Minnesota-connected companies | Star Tribune | 4/1/2020

Purchase: Order Reprint Medical-device maker Abbott Laboratories is rolling out a new desktop device that can detect coronavirus in five minutes in many cases without a patient leaving the doctor’s office. Abbott’s new test … point-of-care COVID tests made by Cepheid and Mesa Biotech , both of California. As of Tuesday, the FDA has granted at least 19 emergency authorizations for COVID-19 detection tests, including five this week …

Bristol-Myers

BMS, bluebird file for approval of CAR-T cell therapy for multiple myeloma - MedCity News | 4/1/2020

Drugmaker Bristol-Myers Squibb and a biotech company with which it has partnered have sent their application to the Food and Drug Administration seeking approval for what could become the first approved CAR-T cell therapy to treat the second most common form of blood cancer. New York-based BMS and Cambridge, Massachusetts-based bluebird bio said Tuesday that they had filed for approval of idecabtagene vicleucel, also known as …

Thermo Fisher Scientific

The Global Bioremediation Market report projects the market to grow at a significant CAGR of 7.72% during the forecast period from 2019 to 2028 | Globe Newswire | 4/1/2020

Thermo Fisher Scientific Inc., Drylet, LLC, Microgen Biotech Ltd., Organic Biotech Pvt. Ltd. and Probiosphere? • Which component type is expected to dominate the market in 2028? • Which medium type is expected to dominate the market in 2028? • Which application type is expected to dominate the market in 2028? • Which region dominated the global bioremediation market in 2018 and what are the expected trends from each of the regions in the …

Amgen

BMS, bluebird file for approval of CAR-T cell therapy for multiple myeloma - MedCity News | 4/1/2020

Drugmaker Bristol-Myers Squibb and a biotech company with which it has partnered have sent their application to the Food and Drug Administration seeking approval for what could become the first approved CAR-T cell … is also developing CC-93269, a T-cell engager, while Amgen has AMG 420, a bispecific antibody. GlaxoSmithKline , meanwhile, expects that the FDA will rule in the first half of this year on belantamab mafodotin …

Pfizer

The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7% | Globe Newswire | 3/30/2020

Pfizer (US), Sandoz (Germany), Biocon (India), Biogen (US), Fresenius Kabi AG (Germany), Boehringer Ingelheim (Germany), Merck KgaA, Mylan (US), Eli Lilly (US), Teva Pharmaceutical (Israel), Dr. Reddy’s Laboratories (India), Amgen (US), Celltrion (South Korea), Samsung Biologics (South Korea), Amega Biotech (Argentina), mAbxience (Switzerland), Probiomed (Mexico), Apotex (Canada), Chong Kun Dang (South Korea), JCR Pharmaceuticals (Japan), Gan & Lee Pharmaceuticals (China), Gedeon Richter (Hungary), Biocad (Russia), Coherus Bioscience (US), and Stada Arzneimittel …

Merck

The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7% | Globe Newswire | 3/30/2020

Merck KgaA, Mylan (US), Eli Lilly (US), Teva Pharmaceutical (Israel), Dr. Reddy’s Laboratories (India), Amgen (US), Celltrion (South Korea), Samsung Biologics (South Korea), Amega Biotech (Argentina), mAbxience (Switzerland), Probiomed (Mexico), Apotex (Canada), Chong Kun Dang (South Korea), JCR Pharmaceuticals (Japan), Gan & Lee Pharmaceuticals (China), Gedeon Richter (Hungary), Biocad (Russia), Coherus Bioscience (US), and Stada Arzneimittel AG (Germany). Research Coverage: The report analyzes the biosimilars market by product, type of manufacturing …

Eli Lilly

The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7% | Globe Newswire | 3/30/2020

Eli Lilly (US), Teva Pharmaceutical (Israel), Dr. Reddy’s Laboratories (India), Amgen (US), Celltrion (South Korea), Samsung Biologics (South Korea), Amega Biotech (Argentina), mAbxience (Switzerland), Probiomed (Mexico), Apotex (Canada), Chong Kun Dang (South Korea), JCR Pharmaceuticals (Japan), Gan & Lee Pharmaceuticals (China), Gedeon Richter (Hungary), Biocad (Russia), Coherus Bioscience (US), and Stada Arzneimittel AG (Germany). Research Coverage: The report analyzes the biosimilars market by product, type of manufacturing, indication, and region.Apart from …

AstraZeneca

Astra, Daiichi’s Enhertu shows early promise in HER2 lung cancer | FierceBiotech | 3/25/2020

After earning an FDA nod for breast cancer in December four months ahead of schedule, AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody-drug conjugate Enhertu is also showing some early promise in other cancer types … antibody-drug conjugate, Roche’s Kadcyla. Moreover, pairing Kadcyla with Puma Biotech’s irreversible pan-HER inhibitor Nerlynx boosted cellular uptake of the drug in lab experiments, the team found. In a different clinical trial , researchers tested …

Qiagen

Global NGS-based RNA-seq Industry | Globe Newswire | 3/18/2020

Biotech AG Illumina, Inc. Macrogen, Inc. Oxford Nanopore Technologies Ltd. Pacific Biosciences of California, Inc. PerkinElmer, Inc. Qiagen NV Thermo Fisher Scientific, Inc. Read the full report: https://www.reportlinker.com/p05799235/?utm_source=GNW I. INTRODUCTION, METHODOLOGY & REPORT SCOPE II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW RNA-Seq: An Introduction A Prelude to NGS-based RNA-seq Market North America: The Largest Market for NGS-based RNA-seq Global Competitor Market Shares …

Inovio

Coronavirus Puts Drug Repurposing on the Fast Track | PR Newswire | 3/17/2020

PALM BEACH, Florida Chinese and western biotech companies have been gearing up to repurpose existing drugs, approved in the West for other viruses, as treatments for the coronavirus outbreak originating in Wuhan . Chinese authorities are … MBRX ), Moderna, Inc. (NASDAQ: MRNA ), Aytu BioScience, Inc. (NASDAQ: AYTU ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), NanoViricides, Inc. (NYSE: NNVC ). “Broad-spectrum agents are ideally suited for outbreak situations where we don’t entirely know what we …

Alexion Pharmaceuticals

CEO of Waltham biotech says he has coronavirus | Boston Globe | 3/17/2020

View Comments The head of Waltham biotech Apellis Pharmaceuticals has tested positive for the new coronavirus and says he started feeling sick about a week after going to a conference previously attended by Biogen employees … blood condition better than a blockbuster drug by Boston-based Alexion Pharmaceuticals. Apellis moved its headquarters from Crestwood, Ky., to Waltham in January. The company has 200 employees in Waltham and about 50 other employees …

Puma Biotechnology

Puma Biotech’s (PBYI) Nerlynx Aids Growth Despite Competition - March 9, 2020 - Zacks.com | 3/9/2020

On Mar 6, we issued an updated research report on Puma Biotechnology, Inc. ( PBYI - Free Report ) . The company’s top line mainly comprises sales of its sole marketed product, Nerlynx. Nerlynx is approved in several countries including the United States and Europe as an extended adjuvant treatment of HER2-positive early-stage breast cancer in adult patients, previously treated with Roche’s ( RHHBY - Free Report ) Herceptin-based adjuvant therapy. The drug was …

TPG Biotech

Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio | 4/28/2020

… TPG Biotech. Concurrent with the financing, venture capitalists Robert Mittendorff, M.D. and Heather Preston, M.D. joined the Board of Directors. Avalyn has just finished enrollment in a clinical study of two-dose regimens of aerosolized pirfenidone (AP01) in patients with idiopathic pulmonary fibrosis (IPF). Proceeds from the Series B expand the company’s pipeline and will support the launch of a Phase II/III trial of AP01 in chronic lung allograft …

Goldman Sachs

Immunomedics Gets Double-Downgrade to Sell From Goldman Sachs - TheStreet | 4/3/2020

Immunomedics receives a double downgrade to sell from buy at Goldman Sachs. Author: Rob Lenihan Publish date: Apr 3, 2020 11:30 AM EDT Immunomedics ( IMMU ) - Get Report received a double downgrade to sell from buy … 2000, which is down 38%, and the SPDR S&P Biotech ETF (XBI) which is down 21%. The FDA is expected to make a decision on sacituzumab govitecan as a third line of therapy in …

Bill & Melinda Gates Foundation

GSK allies with Innovax for COVID-19 vaccine R&D project | FierceBiotech | 4/3/2020

… GSK’s partners has early evidence an adjuvant works with COVID-19 vaccines. (GlaxoSmithKline) GlaxoSmithKline has teamed up with Xiamen Innovax Biotech to evaluate a vaccine against the novel coronavirus behind the COVID-19 pandemic. The … by the COVID-19 Therapeutics Accelerator, an initiative involving the Bill & Melinda Gates Foundation. The accelerator is screening compounds shared by Big Pharma companies for efficacy against SARS-CoV-2. Read more on …

Zacks Investment Research

Puma Biotech (PBYI) Down 44% Since Last Earnings Report: Can It Rebound? | Yahoo News | 3/21/2020

Puma Biotech (PBYI) Down 44% Since Last Earnings Report: Can It Rebound? Zacks Equity Research Reblog It has been about a month since the last earnings report for Puma Biotech (PBYI). Shares have lost about … issued any earnings estimate revisions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report …

Morgan Stanley

PLUG, Z among premarket gainers - Senseonics Holdings, Inc. (NYSEMKT:SENS) | Seeking Alpha | 2/20/2020

Brickell Biotech BBI +64% on positive sofpironium bromide data. Adesto Technologies IOTS +55% on being acquired by Dialog Semiconductor. Stamps.com STMP +39% on Q4 results . E TRADE Financial ETFC +24% on being acquired by Morgan Stanley. Domino’s Pizza DPZ +19% on Q4 results . Community Health Systems CYH +17% on Q4 results . Constellium SE CSTM +15% on Q4 results . Senseonics Holdings (NYSEMKT: SENS ) +14% . Hepion Pharmaceuticals (NASDAQ: HEPA ) +11% . as anti …

NCI

PDS Biotechnology to Present at Noble Capital Markets’ 16th Annual Small & Microcap Investor Conference | Globe Newswire | 2/17/2020

PRINCETON, N.J., Feb. 17, 2020 (GLOBE NEWSWIRE) – PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Dr … HPV-expressing cancers. In partnership with Merck, PDS Biotech is advancing a combination of PDS0101 and KEYTRUDA ® to a Phase 2 study in first line treatment of recurrent or metastatic head and neck cancer. In …

Wellcome Trust

A coalition backed by Bill Gates is funding biotechs that are scrambling to develop vaccines for the deadly Wuhan coronavirus | Business Insider | 1/23/2020

biotech Moderna said Thursday it is working with the National Institutes of Health to develop a coronavirus vaccine, as the deadly virus has spread beyond China in recent days. The effort is funded by the Coalition for Epidemic Preparedness Innovations , a group started by Norway and India, the Bill & Melinda Gates Foundation, the Wellcome Trust, and the World Economic Forum. CEPI is also supporting vaccine-development efforts from the biotech

Ladenburg Thalmann

Vaccine makers tap into virus-driven rally to raise money | MSN | 1/22/2020

… early trade Wednesday on concerns about dilution. “We don’t expect Novavax will run human trials without non-dilutive government funding,” Ladenburg Thalmann’s Michael Higgens wrote in a note. “The timing for such support in our … Raymond James’ Chris Meekins on Tuesday. The SPDR S&P Biotech (XBI) exchange-traded fund has climbed 13% over the last year, while the S&P 500 (SPX) has gained 26 …

Zacks Equity Research

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? | Zacks | 1/13/2020

You follow Sector ETF - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article The Invesco Dynamic Biotechnology & Genome ETF ( PBE - Free Report ) was launched on 06/23/2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity market. Retail and institutional investors increasingly turn to passively managed …

PNC Financial Services Group

The local companies that saw the biggest increases, declines in the stock market | The Business Journals | 1/5/2020

Pittsburgh Business Times Jan 5, 2020, 8:37am EST Three of Pittsburgh’s publicly traded companies — a biotech firm, a manufacturer and a water treatment provider — racked up triple-increases in their stock price over 2019. Krystal … in the Pittsburgh region, closing at $257.41. The second-highest, PNC Financial Services Group Inc. (NYSE: PNC), saw its share price jump 39 percent during 2019. Fifteen local companies on public stock exchanges, either in …

Baxter International

Drug Patent Database Subscription: A Review of Drug Patent Expiry Dates | PR Newswire | 12/31/2019

Baxter International Bayer Schering Pharma AG Beximco Pharmaceuticals Ltd Bial Biocon Biogen Biolex Boehringer-Ingelheim Chugai Pharmaceutical Co. Clovis Oncology Concordia Healthcare Daiichi Sankyo Dainippon Sumitomo Pharma Dr. Reddy’s Laboratories Eisai Elder Pharmaceuticals Eli Lilly and Company Emcure Pharmaceuticals Emergent BioSolutions GlaxoSmithKline Glenmark Pharmaceuticals GPC Biotech Grifols Grindeks G.F. Harvey Company Huadong Medicine Hoffmann-La Roche Horizon Pharma Hovione Incepta Pharmaceuticals Johnson & Johnson Julphar Juno Therapeutics Kimia Farma Kyowa Hakko …

Cantor Fitzgerald

Sarepta in $1.1 billion licensing deal with Roche - The Boston Globe | 12/23/2019

… plunged more than 50 percent from July through September amid bad news from the Food and Drug Administration, the Cambridge biotech got a boost Monday when it announced a $1.1 billion licensing deal with the … win for the company,” said Alethia Young, an analyst for Cantor Fitzgerald, in a note to investors. “We think validation from a company like Roche performing extensive diligence and choosing to partner should significantly increase …

Samsara BioCapital

In a shift toward venture capital fundraising, FORMA brings in $100 million | STAT | 12/19/2019

Biotech In a shift toward venture capital fundraising, FORMA Therapeutics brings in $100 million By Kate Sheridan @sheridan_kate December 19, 2019 Red blood cells from a person with sickle cell anaemia. Jonathan Armstrong/Wellcome … investors that includes RA Capital, Cormorant Capital, Wellington Management, and Samsara BioCapital, among others. Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months! GET STARTED …

Boxer Capital

Black Diamond Therapeutics Closes $85 Million Series C Financing | PR Newswire | 12/5/2019

… small molecule, tumor-agnostic therapies, today announced the completion of an oversubscribed Series C financing of $85 million led by Boxer Capital of the Tavistock Group. Additional new investors Wellington Management Company, BVF Partners L.P … An industry leader with expertise in strategy and operations in biotech and a wide range of pioneering therapeutic technologies, Sam currently serves as CEO of CRISPR Therapeutics AG. He joined CRISPR in 2015 in the …

Mission Bay Capital

Astellas and MBC BioLabs Announce Golden Ticket Winners - Supporting Biotech Start-Ups to Accelerate Innovative Science | PR Newswire | 12/5/2019

MENLO PARK, Calif. Astellas Venture Management (President: Shunichiro Matsumoto , Ph.D., MBA, “AVM”), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., “Astellas”), and Mission Bay Capital BioLabs (“MBC BioLabs”), a life-science incubator, today announced AmbAgon Therapeutics and Gordian Biotechnology as the winners of the Astellas-sponsored “Golden Ticket Competition.” The award supports advancing early-stage companies’ pre-clinical scientific discoveries …

Astellas Venture Management

Astellas and MBC BioLabs Announce Golden Ticket Winners - Supporting Biotech Start-Ups to Accelerate Innovative Science | PR Newswire | 12/5/2019

MENLO PARK, Calif. Astellas Venture Management (President: Shunichiro Matsumoto , Ph.D., MBA, “AVM”), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., “Astellas”), and Mission Bay Capital BioLabs (“MBC BioLabs”), a life-science incubator, today announced AmbAgon Therapeutics and Gordian Biotechnology as the winners of the Astellas-sponsored “Golden Ticket Competition.” The award supports advancing early-stage companies’ pre-clinical scientific discoveries …

RA Capital Management

Black Diamond Therapeutics Closes $85 Million Series C Financing | PR Newswire | 12/5/2019

… Management, funds managed by Janus Henderson Investors, Casdin Capital, and Logos Capital joined current investors Versant Ventures, New Enterprise Associates, RA Capital Management, Nextech Invest, Invus, Perceptive Advisors, City Hill Ventures, and Roche Venture Fund … An industry leader with expertise in strategy and operations in biotech and a wide range of pioneering therapeutic technologies, Sam currently serves as CEO of CRISPR Therapeutics AG. He joined CRISPR in 2015 in the …

Wellington Management

Black Diamond Therapeutics Closes $85 Million Series C Financing | PR Newswire | 12/5/2019

… of an oversubscribed Series C financing of $85 million led by Boxer Capital of the Tavistock Group. Additional new investors Wellington Management Company, BVF Partners L.P., Deerfield Management, funds managed by Janus Henderson Investors, Casdin … An industry leader with expertise in strategy and operations in biotech and a wide range of pioneering therapeutic technologies, Sam currently serves as CEO of CRISPR Therapeutics AG. He joined CRISPR in 2015 in the …

SR One

East/West CEO Brings Together Biopharma Trailblazers to Discuss Key Industry Issues - Exclusive savings through Friday with special Cyber Week sale | Benzinga | 12/5/2019

SAN FRANCISCO , Dec. 5, 2019 /PRNewswire-PRWeb/ – LeadingBiotech , an exclusive event series bringing together senior-level biopharma leaders through off-the-record collaboration and dialogue, today announces key issues to be discussed at its East … Intensity Therapeutics Diego Miralles - CEO, Vividion Therapeutics Simeon George - CEO, SR One See full agenda here . Save 50% on registration through Dec. 6th exclusively for Cyber Week. Click here to register and use code CYBER …

C-Bridge Capital

Global Biosimilars Partnering Deals, Terms and Agreements 2014-2019 - Deal Type, Industry Sector, Stage Of Development, Technology Type, Therapeutic Indication | Benzinga | 12/5/2019

C-Bridge Capital Catalent Pharma Solutions CEA-Leti Celares Celltrion Cipla CJ Corp Clinigen Cobra Biologics Coherus Biosciences Cook Pharmica CR Pharma Daiichi Sankyo Diabeloop Dr. Reddy’s Laboratories Dyadic International EirGenix EMD Millipore Epirus Biopharmaceuticals Epivax European Commission Ewopharma Fujifilm Kyowa Kirin Biologics Fuji Pharma Genentech Hadasit Medical Research Services and Development Helvetic Biopharma Henlius Biotech Hikma Pharmaceuticals Hoffmann La Roche Horizon 2020 Hospira Ipca Laboratories Jacobson Pharma JHL Biotech

Janus Henderson Investors

Black Diamond Therapeutics Closes $85 Million Series C Financing | PR Newswire | 12/5/2019

… Boxer Capital of the Tavistock Group. Additional new investors Wellington Management Company, BVF Partners L.P., Deerfield Management, funds managed by Janus Henderson Investors, Casdin Capital, and Logos Capital joined current investors Versant Ventures, New Enterprise … An industry leader with expertise in strategy and operations in biotech and a wide range of pioneering therapeutic technologies, Sam currently serves as CEO of CRISPR Therapeutics AG. He joined CRISPR in 2015 in the …

BVF Partners

Black Diamond Therapeutics Closes $85 Million Series C Financing | PR Newswire | 12/5/2019

… Series C financing of $85 million led by Boxer Capital of the Tavistock Group. Additional new investors Wellington Management Company, BVF Partners L.P., Deerfield Management, funds managed by Janus Henderson Investors, Casdin Capital, and Logos … An industry leader with expertise in strategy and operations in biotech and a wide range of pioneering therapeutic technologies, Sam currently serves as CEO of CRISPR Therapeutics AG. He joined CRISPR in 2015 in the …

Alexandria Venture

ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases | Benzinga | 12/4/2019

… Bpifrance and Pfizer Ventures co-led international investor syndicate – Marseille, France, December 04, 2019, 6:45 AM CET – ImCheck Therapeutics, a biotech company developing a first-in-class antibody to activate gamma delta (gd) T cells … and joined by new investors Wellington Partners, Agent Capital and Alexandria Venture Investments. Life Sciences Partners (LSP), Gimv, Idinvest Partners, Kurma Partners and Boehringer Ingelheim Venture Fund that contributed to the 2017 €20 Million Series …

Alexandria Venture Investments

ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases | Benzinga | 12/4/2019

… Bpifrance and Pfizer Ventures co-led international investor syndicate – Marseille, France, December 04, 2019, 6:45 AM CET – ImCheck Therapeutics, a biotech company developing a first-in-class antibody to activate gamma delta (gd) T cells … and joined by new investors Wellington Partners, Agent Capital and Alexandria Venture Investments. Life Sciences Partners (LSP), Gimv, Idinvest Partners, Kurma Partners and Boehringer Ingelheim Venture Fund that contributed to the 2017 €20 Million Series …

JP Morgan

What’s Rubius Therapeutics, Inc. (RUBY) Downside After Forming Multiple Bottom? | Finance Recorder | 12/4/2019

… is 46.79% above currents $8.4 stock price. Rubius Therapeutics had 5 analyst reports since June 26, 2019 according to SRatingsIntel. JP Morgan maintained Rubius Therapeutics, Inc. (NASDAQ:RUBY) on Friday, November 15 with “Overweight” rating … also Globenewswire.com with their article: “Rubius Therapeutics Added to Nasdaq Biotechnology Index – GlobeNewswire” published on December 17, 2018, Globenewswire.com published: “TGI Fridays and Allegro Merger Corp. Announce Merger – GlobeNewswire” on November 08, 2019. More interesting …

Harvard Medical School

Regenacy Pharmaceuticals Raises $30 Million in Series A Financing | Business Wire | 3/25/2020

… was co-led by Cobro Ventures and Taiwania Capital Management Corporation, with participation from 3E Bioventures Capital, Yonjin Capital, VIVA Biotech Holdings, TA YA VENTURE HOLDINGS LIMITED, and other undisclosed private investors. “We are fortunate … evaluating ricolinostat,” said William Chin, M.D., Professor of Medicine Emeritus, Harvard Medical School, Scientific Advisory Board Member and Board of Directors Member of Regenacy. “To me, the scientific reasoning behind HDAC6 inhibition for this indication …

Beth Israel Deaconess Medical Center

8 Biotechs With Coronavirus Vaccines In Development | Yahoo News | 3/16/2020

… to make available 1 million doses of the vaccine by end of 2020. Applied DNA Sciences Inc (NASDAQ: APDN ) & Takis Biotech Type of Vaccine: Linear DNA vaccine Stage of Development: Preclinical After revealing Feb. 7 … week that it has entered into a collaboration with the Beth Israel Deaconess Medical Center to support development of a vaccine for COVID-19. The company and hospital have embarked on preclinical testing of multiple …

MD Anderson Cancer Center

Advances in Treatments are Leading to a Decline in Deaths from Cancer | PR Newswire | 3/4/2020

… including Xynomic Pharmaceuticals Holdings, Inc. (OTCPK: XYNO), BridgeBio Pharma (NASDAQ: BBIO ), and Bristol-Myers Squib. (NYSE: BMY ). One company, Oncolytics Biotech Inc., (NASDAQ: ONCY ) (TSX: ONC), is making significant strides in developing a new drug … said Dr. Patrick Hwu , division head of cancer medicine at MD Anderson Cancer Center in Houston . One of the biggest advances is the development of immunotherapies including Keytruda, also known as pembrolizumab. Keytruda is one …

Mayo Clinic

Pharmacy Times Continuing Education™ to Present Three Educational Symposia at the Hematology/Oncology Pharmacy Association 16th Annual Conference | Business Wire | 2/12/2020

… in Asheville, North Carolina. This activity is supported by an educational grant from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc. and is jointly sponsored by Rutgers Biomedical and Health Sciences, Ernest Mario School … pharmacy manager, M Health Fairview, and assistant professor of pharmacy, Mayo Clinic School of Medicine in Maple Grove, Minnesota. This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech

Hackensack Meridian

Barer Institute Announces Founding Board Members | PR Newswire | 1/14/2020

Hackensack Meridian Center for Discovery and Innovation, and advisor to the Israel Biotech Fund. Dr. Barer is a co-founder of Celgene Corporation and served as Celgene’s Executive Chairman, President, CEO, and COO. Richard Axel , M.D., is the recipient of the 2004 Nobel Prize in Physiology or Medicine. He is University Professor in the departments of neuroscience, biochemistry and molecular biophysics, and pathology at Columbia University , Co-director of the …

Memorial Sloan Kettering

EMBARGOED-Eli Lilly to put Loxo executives in charge of new cancer research unit | Yahoo News | 12/5/2019

… will create a new cancer research division that will be run by top executives from Loxo Oncology, a cancer-focused biotech company it acquired earlier this year.” data-reactid=”13” Dec 5 (Reuters) - U.S. drugmaker … serves as chief of the early drug development service at Memorial Sloan Kettering Cancer Center in New York. They will report to Daniel Skovronsky, Lilly’s chief scientific officer. “We intend to create a balanced pipeline …

NYU Langone Medical Center, New York NY

Enzo Biochem Issues Open Letter to Shareholders | Business Wire | 12/5/2019

… in a standard interview process or complete a customary questionnaire), both lack any identifiable experience with a laboratory diagnostics or biotech company like Enzo. Furthermore, it is worth pointing out that one of these nominees … pathology and microbiology, having completed a 32-year career at NYU Langone Medical Center, in addition to his ownership in the Village Lab, a NYC tropical diseases laboratory. He is the author of approximately 100 …

Massachusetts General Hospital

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Cleveland HeartLab Clinigene International Comprehensive Biomarker Center (formerly Febit) Covance Crelux Critical Diagnostics Critical Path Institute (C-Path) [US] CTI Biotech Daiichi Sankyo Dako (now part of Agilent) Dana-Farber Cancer Institute [US] Danaher DaVita … Consortium (ICGC) Les entreprises du médicament (LEEM) [ France ] Malmö University Massachusetts General Hospital Max Planck Institute for Molecular Genetics [ Germany ] National Academy of Sciences National Cancer Institute (NCI) [US] National Health Service (NHS) [UK] National …

Memorial Sloan Kettering Cancer Center

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Teva) Charles River Laboratories Chronix Biomedical Chugai Pharmaceutical Ciphergen Biosystems Clarient Diagnostic Services Cleveland HeartLab Clinigene International Comprehensive Biomarker Center (formerly Febit) Covance Crelux Critical Diagnostics Critical Path Institute (C-Path) [US] CTI Biotech Daiichi Sankyo Dako (now part of Agilent) Dana-Farber Cancer Institute [US] Danaher DaVita Labs DiaGenic Durin Technologies DxS (now part of QIAGEN) EKO Diagnostic Eli Lilly and Co. Epic Sciences Epigenomics Epistem EQT Evotec Exact …

Cleveland Clinic

JanOne Names Tony Giordano, Ph.D., as Chief Scientific Officer | PR Newswire | 12/3/2019

… to his role with JanOne, he also serves as Senior Director of Special Projects in the Innovations Center at the Cleveland Clinic. “I’m delighted to announce Dr. Giordano’s appointment as Chief Scientific Officer,” said Eric … bioscientist, Dr. Giordano has held senior positions at cutting-edge biotechnology companies. As President of Sulfagenix, Inc., he managed the completion of a Phase 1 clinical study, GRAS affirmation and launch of medical food product …

Cleveland Clinic, Cleveland OH

JanOne Names Tony Giordano, Ph.D., as Chief Scientific Officer | PR Newswire | 12/3/2019

… to his role with JanOne, he also serves as Senior Director of Special Projects in the Innovations Center at the Cleveland Clinic. “I’m delighted to announce Dr. Giordano’s appointment as Chief Scientific Officer,” said Eric … bioscientist, Dr. Giordano has held senior positions at cutting-edge biotechnology companies. As President of Sulfagenix, Inc., he managed the completion of a Phase 1 clinical study, GRAS affirmation and launch of medical food product …

Dana-Farber Cancer Institute, Boston MA

Next-Generation Medicine Innovation and Manufacturing Center Planned for Boston | 12/3/2019

… Innovation and Manufacturing Center Planned for Boston December 3, 2019 Source: Harvard University Share A group of Massachusetts academic, healthcare, biotech, and biopharma industry leaders have come together to establish a new center to address … Medical Center, Boston Children’s Hospital, Brigham and Women’s Hospital, the Dana-Farber Cancer Institute, Massachusetts General Hospital, MilliporeSigma, and the Commonwealth of Massachusetts. The $50 million center will be an independent nonprofit organization located in …

Massachusetts General Hospital, Boston MA

Next-Generation Medicine Innovation and Manufacturing Center Planned for Boston | 12/3/2019

… Innovation and Manufacturing Center Planned for Boston December 3, 2019 Source: Harvard University Share A group of Massachusetts academic, healthcare, biotech, and biopharma industry leaders have come together to establish a new center to address … Hospital, Brigham and Women’s Hospital, the Dana-Farber Cancer Institute, Massachusetts General Hospital, MilliporeSigma, and the Commonwealth of Massachusetts. The $50 million center will be an independent nonprofit organization located in the greater Boston area …

OhioHealth

Global Stem Cell Therapy Contract Manufacturing Market Research 2019-2030: Source of Stem Cells, Types of Stem Cells, Size of Contract Service Provider Company, Scale of Operation, Key Regions | PR Newswire | 12/3/2019

Global Stem Cell Therapy Contract Manufacturing Market Research 2019-2030: Source of Stem Cells, Types of Stem Cells, Size of Contract Service Provider Company, Scale of Operation, Key Regions News provided by Research and Markets Dec 03, 2019, 12:00 ET DUBLIN , Dec. 3, 2019 /PRNewswire/ – The “Stem Cell Therapy Contract Manufacturing Market, 2019-2030” report has been added to ResearchAndMarkets.com’s offering. The Stem Cell Therapies Contract Manufacturing Market, 2019 - 2030 report features …

University of Texas MD Anderson Cancer Center

The return of the megamerger | 12/2/2019

… businesses that fell outside their core mandate of discovering new medicines. A number of midsize cancer- and gene therapy–focused biotech firms were gobbled up, and more are likely to be absorbed into larger companies … He also has leadership and crisis experience: he steered the University of Texas MD Anderson Cancer Center out of financial and legal trouble, and while he was at the University of Pennsylvania, he took responsibility …

The University of Texas MD Anderson Cancer Center

The return of the megamerger | 12/2/2019

… businesses that fell outside their core mandate of discovering new medicines. A number of midsize cancer- and gene therapy–focused biotech firms were gobbled up, and more are likely to be absorbed into larger companies … treatments. He also has leadership and crisis experience: he steered the University of Texas MD Anderson Cancer Center out of financial and legal trouble, and while he was at the University of Pennsylvania, he took …

UT Southwestern Medical Center

Stem Cell Technology: The Only Constant Is Change | 12/2/2019

… well as the development of reprogramming techniques and the generation of induced pluripotent stem cells (iPSCs). More recently, advances in biotechnology and genome editing have fostered a modern evolution of stem cell advances that shows … on wound healing and aging. Jun Wu, PhD, Assistant Professor, UT Southwestern Medical Center In collaboration with Jun Wu, PhD, assistant professor at UT Southwestern Medical Center and a former postdoc in the Belmonte laboratory …

UPMC

Drugmakers Betting Big On Gene Therapy By Investing Combined $2B Into Manufacturing Pricey Treatments | Kaiser Health News | 12/2/2019

… are the potential rewards. In other pharmaceutical news: a high-stakes bet on heart drugs, an invite-only club for biotech CEOs, President Donald Trump’s importation plan, and more. Reuters: Pfizer, Novartis Lead $2 Billion … Hellmann, 12/1) Stat: Biogen Strikes Value-Based Contracting Deal With UPMC Health In a twist on value-based contracting, a drug maker has agreed to offer a larger discount that a commercial health plan will …

Ascension

Industry Voices—How healthcare organizations can navigate the emerging data economy | FierceHealthcare | 12/2/2019

Innovative approaches to anonymization and aggregation—some using new technologies like blockchain, others using new models of data rights—are allowing data users to extract valuable information without compromising patients’ rights or their privacy. RELATED: Lawsuit accuses University of Chicago of sharing identifiable patient data with Google Wall Street investors do not care about individual patients, only about aggregate trends, so they are perfectly aligned with this desire for privacy …

Northwell Health

Northwell May Host Lab to Cure AIDS; AIDS Memorial May See AIDS Cure | 12/1/2019

The 2019 Gay Pride parade drew thousands to the Village, here shown in front of Northwell Health’s facility. Photo by Ismael Ramirez. Northwell May Host Lab to Cure AIDS By George Capsis Iran-born Kambiz … to Cure AIDS is the first charitable 501(c)3 biotechnology venture that obtained a license to use cellular technology to research, develop, and commercialize a global cure for AIDS. Thanks to George’s pioneering leadership …

Medical University of South Carolina

Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Medical Devices Pipeline Assessment, 2019 | 12/1/2019

… Overview 44 5.3 Affinergy LLC Company Overview 45 5.3.1 Affinergy LLC Pipeline Products & Ongoing Clinical Trials Overview 45 5.4 Am Biotechnologies, LLC Company Overview 46 5.4.1 Am Biotechnologies, LLC Pipeline Products & Ongoing Clinical Trials Overview … of Technology Pipeline Products & Ongoing Clinical Trials Overview 98 5.39 Medical University of South Carolina Company Overview 100 5.39.1 Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 100 5.40 Monash University Company …

Mount Sinai Hospital

Health Canada approves Kadcyla® (trastuzumab emtansine) for the treatment of HER2-positive early breast cancer after surgery(1) | The Wapakoneta Daily News | 11/28/2019

… with this disease – an important step forward in treating HER2-positive eBC,” says Dr. Christine Brezden-Masley , Medical Oncologist at Mount Sinai Hospital, Toronto .”The goal of treating early breast cancer is to provide people … in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader …

Moffitt Cancer Center

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | PR Newswire | 11/28/2019

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool News provided by Research and Markets Nov 28, 2019, 07:00 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Genome Editing Services Market-Focus on CRISPR 2019-2030” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an …

Tufts Medical Center

YOUR HEALTH: A hot rod lover with cancer found his genes could save his life | 11/28/2019

… Tufts Medical Center. “I would have estimated a life expectancy of under a year if not six months.” Once cancer has spread, most doctors rule out surgery and radiation, the standard treatments for early stage prostate cancer. That’s when Dr. Mathew tried something cutting-edge for prostate cancer. He removed John’s tumor and sent it to a Boston biotech lab. Technicians analyzed the genes known to drive tumor growth. “In …

Tenet Healthcare Corporation

Top-Ranked ETFs & Stocks to Feast on Thanksgiving and After | Zacks | 11/27/2019

… P 500 breached the 3,100 level while the Dow Jones topped the 28,000 milestone. Stellar show by the tech and biotech stocks has made this uptrend possible. The S&P 500 is up 25% in … Carnival Inc. ( SCVL - Free Report ) – P/E 12.61x, Rank 1 Tenet Healthcare Corporation ( THC - Free Report ) – P/E 12.24x, Rank 2 Alaska Air Group Inc. ( ALK - Free Report ) – P/E 10.93x, Rank 2 Want key …

Aetna

Health Care Reform Articles - December 3, 2019 | 12/4/2019

… medical costs—for a while. But under the Trump administration, health-care sector mergers (such as Cigna-Express Scripts, CVS-Aetna and Optum-DaVita) have effectively reduced competition and increased pricing power. To address this … Association and some of the nation’s largest individual hospital systems; biotech trade group BIO; the health care executive roundtable Healthcare Leadership Council; and a series of trade associations representing smaller slices of the industry like …

UnitedHealthcare

In Trump’s America, the H-1B dream has turned into a bureaucratic nightmare for skilled Indians | 12/3/2019

… in environmental engineering, and after a few internships where he picked up programming skills, he was hired in 2010 by UnitedHealthcare, a Fortune 500 insurance company based in Minnesota. He loved his job streamlining its … as a $250,000-a-year analyst to evaluate Silicon Valley biotech startups. The petitioner had already qualified for a H-1B1 visa, a temporary work permit for Singaporeans and Chileans that has the same requirements …

Anthem

🌎 The Week Ahead for 12/1/2019 | 12/1/2019

… proves that anyone who gets in now could turn $1,000 into $1.57 Million (Ad) On September 10, 2018, a tiny biotech firm won a patent on a new treatment that can “Cut & Paste” any disease … Analog Devices, Inc. ( ADI ) quarterly $0.54 1.91% 12/5/2019 12/6/2019 12/17/2019 Anthem Inc ( ANTM ) quarterly $0.80 1.23% 12/4/2019 12/5/2019 12/20/2019 Arthur J Gallagher & Co ( AJG ) quarterly $0.43 1.92% 12/5/2019 12/6/2019 12/20/2019 Avery Dennison Corp ( AVY ) quarterly …

Molina Healthcare

Google Alert - network | 11/24/2019

… to Medicaid recipients in Charleston Live 5 News WCSC Healthcare network to give away 200 Turkeys to Medicaid recipients in … Molina Healthcare in partnership with Fetter Health Care Network and … Flag as irrelevant Merkel’s CDU … to … Flag as irrelevant BIRAC, IAN come together to launch biotech-focused angel funding network Economic Times NEW DELHI: Biotechnology Industry Research Assistance Council (BIRAC), in partnership with Indian Angel Network (IAN), has announced the …

Humana

VantagePoint | Hot Stocks Outlook for November 22, 2019 | 11/22/2019

… VantagePoint Hot Stocks Outlook for November 22, 2019 By In this week’s video, VantagePoint Software reviews forecasts for Centene (CNC) , Humana (HUM) Ironwood Pharmaceuticals (IRWD) , CRISPR Therapeutics (CRSP), Walt Disney (DIS) and Harley-Davidson (HOG … highlighting over the past couple of months here. Healthcare and biotech stocks doing extremely well, so we brought in United Healthcare several weeks ago. Here’s Centene, Humana, we’ll take a look at that. We’ve got …

Health Net

Allegheny Health Networks Dr. Susan Manzi receives prestigious award for outstanding contributions to the field of rheumatology | 11/21/2019

Posted November 20th, 2019 for Allegheny Health Network Wednesday, November 20, 2019 PITTSBURGH – Allegheny Health Network’s Susan Manzi, MD, MPH , is the recipient of the American College of Rheumatology’s 2019 Distinguished Clinical Investigator Award. She … boards for the FDA and more than 20 pharmaceutical and biotech companies, and has chaired or served on numerous NIH study sections and data safety monitoring boards. At the AHN Autoimmunity Institute , based at West …

Oscar Health

We just got a look at the latest financials for health startups like Bright and Oscar. They reveal the challenges facing the insurers as they keep growing their footprints. | Business Insider | 11/19/2019

… that technology can help them provide better care to their members. Business Insider looked through regulatory filings of five startups — Oscar Health, Devoted Health, Bright Health, Clover Health, and Alignment Healthcare — to get a sense … 925 million. And in July, the company started working with biotech giant Genentech to develop therapeutics. Over the past year, the company has been building out its Clover Assistant program, software that can assist doctors …

Clover Health

We just got a look at the latest financials for health startups like Bright and Oscar. They reveal the challenges facing the insurers as they keep growing their footprints. | Business Insider | 11/19/2019

… better care to their members. Business Insider looked through regulatory filings of five startups — Oscar Health, Devoted Health, Bright Health, Clover Health, and Alignment Healthcare — to get a sense of how they fared in the … 925 million. And in July, the company started working with biotech giant Genentech to develop therapeutics. Over the past year, the company has been building out its Clover Assistant program, software that can assist doctors …

Cigna

“Apparently Kudlow + Retail = 28k” Vista Partners Daily Market Recap 11/15/19 | 11/16/2019

… share. This week reports surfaced that publicly traded private equity firm KKR (KKR $29.84 +1.36%) is preparing a buyout plan. Cigna (CI) closed +3.33% closing at $196.01/share. Worldwide, the fertility treatment market is severely … at $.254/share. The 52-wk range is $.22 – $.63. Biotech The Ishares Nasdaq Biotechnology ETF (IBB) moved -.66% closing at $109.85 & the NYSE Arca Biotech Index (^BTK) closed at 4,670.23 +1.95%. Johnson & Johnson (JNJ …

Healthspan

Novel therapeutic approach to cardiovascular disease from SENS Research Foundation flagship research program graduates from laboratory to the biotech world | Globe Newswire | 11/14/2019

… Greve’s Kizoo Technology Capital, part of the Forever Healthy Group and one of the premier organizations focusing on accelerating rejuvenation biotechnologies. It also includes Oculus co-founder Michael Antonov through Tubus, LLC, and financier Harald … initiating new projects, and helping generate the next wave of healthspan spinouts.” Science and technology investor and longtime SRF board member Jim O’Neill has stepped in to lead the SENS Research Foundation as interim CEO …

Independence Blue Cross

Interpace Diagnostics Changes Name to Interpace Biosciences; Announces Plans for Next Phase of Growth and Third Quarter 2019 Financial Results | Financial Buzz | 11/13/2019

… Pharma Solutions, that uses its proprietary test systems and platforms to support drug discovery and development valued by pharmaceutical and biotechnology companies. Interpace Biosciences will continue to trade on NASDAQ as IDXG. Interpace Biosciences recognized … and; Announced that THyGeNEXT® and ThyraMIR® are now covered by Independence Blue Cross for its nearly 2.5 million members in Philadelphia and Southeastern PA. Clinical Validation Announcements Announced the publication of two peer-reviewed journal …

MedPartners

Alentis raises A round to advance drug against novel liver disease target | FierceBiotech | 4/29/2019

Apr 29, 2019 7:00pm Alentis CEO Markus Ewert (BioMedPartners) Alentis Therapeutics has raised CHF 12.5 million ($12.2 million) to take an advanced liver disease drug toward clinical development. The series A tees a team led … Ewert said. FREE DAILY NEWSLETTER Like this story? Subscribe to FierceBiotech! Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for …

Melinda Gates

GSK allies with Innovax for COVID-19 vaccine R&D project | FierceBiotech | 4/3/2020

… GSK’s partners has early evidence an adjuvant works with COVID-19 vaccines. (GlaxoSmithKline) GlaxoSmithKline has teamed up with Xiamen Innovax Biotech to evaluate a vaccine against the novel coronavirus behind the COVID-19 pandemic. The … the COVID-19 Therapeutics Accelerator, an initiative involving the Bill & Melinda Gates Foundation. The accelerator is screening compounds shared by Big Pharma companies for efficacy against SARS-CoV-2. Read more on …

Michael Moore

Oncolytics Biotech® Announces Publication of Pelareorep’s Clinical Benefit Against KRAS Mutated Colorectal Cancer | PR Newswire | 4/2/2020

SAN DIEGO and CALGARY, Alberta , April 2, Oncolytics Biotech ® Inc. (NASDAQ: ONCY ) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced positive clinical data published in a peer-reviewed journal highlighting … looking statements, except as required by applicable laws. Company Contact Michael Moore Investor Relations & Corporate Communications +1-858-886-7813 [email protected] Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +1-212-915-2564 [email protected] SOURCE Oncolytics Biotech® Inc. Related …

Janet Woodcock

FiercePharmaAsia—Legend’s U.S. IPO; U.S. reliance on China drugs; Harbour-Mount Sinai team-up | 3/13/2020

China’s Genscript Biotech is planning to spin off its cell therapy unit and Johnson & Johnson CAR-T partner Legend Biotech for a U.S. IPO. The FDA is not sure exactly to what extent the U.S … the coronavirus outbreak. But how dependent is it? According to Janet Woodcock, the FDA’s director of the Center for Drug Evaluation and Research, the agency doesn’t know how much API Chinese facilities are producing for …

George W. Bush

RELIEF THERAPEUTICS Holding SA (SIX: RLF) announces the proposal of Prof. Jonathan Javitt, M.D., M.P.H., at the upcoming general assembly as Vice Chairman of the Board | Business Wire | 3/11/2020

… primary cause of death in those patients who succumb to COVID-19 infection. RLF-100, acquired by Relief from Mondo Biotech, AG, has an Investigational New Drug (IND) from the US Food and Drug Administration … Clinton, and Bush ’43). He joined the administration of President George W. Bush on the afternoon of September 11, 2001 and was subsequently appointed as a Special Employee of the Office of the Undersecretary of …

Anthony Fauci

The CEO of the buzzy biotech that’s working on a potential coronavirus vaccine just pledged he won’t set a high price for the shot (MRNA) | Business Insider | 3/4/2020

… The first potential vaccine for the novel coronavirus is set to begin human testing soon. The CEO of Moderna, the biotech company that is developing the vaccine, pledged thoughtfulness in setting a potential price. “There … that it is “super early” in the vaccine-development process. Anthony Fauci, head the National Institutes of Health’s infectious-disease unit, has said it will take 12 to 18 months to determine the safety and …

Daniel O’Day

CEO Daniel O’Day explains why Gilead paid $4.9 billion for Forty Seven - STAT | 3/2/2020

Biotech CEO Daniel O’Day explains why Gilead paid $4.9 billion for Forty Seven By Matthew Herper @matthewherper March 2, 2020 STAT G ilead’s board hired CEO Dan O’Day a year ago to look for new areas of growth for the $22 billion biotech. On Monday, the company announced that it would spend $4.9 billion to purchase Forty Seven, a developer of new cancer drugs. The deal is likely to be …

Bob Iger

Coronavirus vaccine developer Moderna soared 30% as US stocks suffered their worst stretch in years. Here are the 10 investors that benefited most — and how much they made. (MRNA) | Business Insider | 2/26/2020

… profiting from the company’s bid to offer a coronavirus vaccine. Moderna spiked 30% between Monday and Tuesday’s trading sessions. The biotech firm was one of the few US stocks to post major gains while the … plunge 5 things to know about Disney CEO Bob Chapek, Bob Iger’s surprise successor GOLDMAN SACHS: Buy these 12 stocks to keep crushing the market as profit margins shrink …

Eva Ehrnrooth

IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer | PR Newswire | 2/25/2020

COPENHAGEN, Denmark , Feb. 25, IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the successful outcome of a scheduled interim analysis of … to note that this hurdle has been successfully crossed,” said Eva Ehrnrooth, MD, PhD, chief medical officer of IO Biotech. “Through this trial, we expect to get a comprehensive data set that paves the way …

Laura Wood

Global Acute Agitation and Aggression Treatment Market Industry Analysis 2019-2027 with Key Market Forecasts | PR Newswire | 2/19/2020

… Lilly and Company Pfizer, Inc. Ono Pharmaceutical Co., Ltd. Otsuka Holdings Co., Ltd. GlaxoSmithKline plc Bristol-Myers Squibb Company Janssen Biotech, Inc. (Johnson & Johnson) H. Lundbeck A/S Key Topics Covered: Market Overview Global Acute … focused, comprehensive and tailored research. Media Contact: Research and Markets Laura Wood , Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 …

Donald Trump

Coronavirus tracker: J&J’s ‘skunkworks,’ Roche’s delivery woes, Sanofi’s travel restrictions and more | FiercePharma | 1/30/2020

… thanks to the numerous Chinese cities in lockdown mode. The travel barriers have proven a complication for delivering diagnostic kits, the company said. Meanwhile, China just approved several new diagnostic kits from Sansure Biotech to help detect cases. To keep its own workforce safe, Sanofi has asked employees to stop travel to and from Wuhan and the Hubei province, Reuters reports , as the case count climbs. The outbreak continues to …

Fred Hutchinson

Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes Disease | Globe Newswire | 1/16/2020

… Application for CUTX-101 to the FDA in the second half of 2020 January 16, 2020 08:30 ET Source: Fortress Biotech, Inc. NEW YORK, Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused … its full potential, including Alexion Pharmaceuticals, Inc., City of Hope, Fred Hutchinson Cancer Research Center, InvaGen Pharmaceuticals Inc. (a subsidiary of Cipla Limited), St. Jude Children’s Research Hospital, and Nationwide Children’s Hospital. For more information …

Severin Schwan

‘Guided-Missile’ Cancer Drugs are the Biotech Sector’s First Major Story of the 2020s | PR Newswire | 1/15/2020

… agents to fight cancer—affectionately dubbed “ guided-missile “ cancer drugs. Cancer treatments are being targeted for drastic improvements by several biotech developers large and small, including Oncolytics Biotech Inc . (NASDAQ: ONCY ) (TSX:ONC), Roche Holding … for now. “We have shifted our technology priorities,” Roche CEO Severin Schwan told Reuters . “Maybe others will be luckier, but we failed to master the complexity.” This is where groups like AstraZeneca PLC are looking …

Bernard Briskin

Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep’s Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma | PR Newswire | 1/13/2020

SAN DIEGO and CALGARY, Alberta , Jan. 13, Oncolytics Biotech ® Inc. (NASDAQ: ONCY ) (TSX: ONC) (TSX: ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today provided a recap of a Key Opinion Leader call … of Medicine , Atlanta, GA. Dr. Flavia Pichiorri Ph.D., Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA and Department of Hematologic Malignancies Translational Science, Beckman Research Institute, City of Hope …

Scott Gottlieb

GenScript Biotech to Host Global Forum on Cell and Gene Therapy and the Booming China Market During JPM Week | PRWeb | 1/10/2020

GenScript Biotech to Host Global Forum on Cell and Gene Therapy and the Booming China Market During JPM Week Share Article Global Forum will gather industry leaders, regulatory agencies, academia, and investors to bring life … Highlights of the agenda include: Keynote by former FDA Commissioner Scott Gottlieb, M.D. Panel discussion on global progress in cell and gene therapy with Legend Biotech, Kite, Ziopharm Oncology, GE Healthcare Life Sciences, Johnson & Johnson …

Mathai Mammen

Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc. | PR Newswire | 12/30/2019

… the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees, from XBiotech Inc., for $750 million . Should Janssen pursue bermekimab indications outside of dermatology, XBiotech may … coping with diseases that have few or no options,” said Mathai Mammen , M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson. “As the only anti-IL1a in clinical development, bermekimab fits this approach perfectly.” About …

Peter Lynch

Who Has Been Buying PCI Biotech Holding ASA (OB:PCIB) Shares? | Yahoo News | 12/23/2019

… for a business. So we’ll take a look at whether insiders have been buying or selling shares in strong PCI Biotech Holding ASA /strong ( a target=”_blank” href=”https://simplywall.st/stocks/no/pharmaceuticals-biotech/ob … would consider it foolish to ignore insider transactions altogether. As Peter Lynch said, ‘insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will …

Walter Klemp

Moleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models | PR Newswire | 12/19/2019

HOUSTON Moleculin Biotech, Inc., (Nasdaq: MBRX ) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the presentation of a poster entitled, “Liposomal … potential expansion of Annamycin to indications beyond acute leukemia,” commented Walter Klemp , Chairman and CEO of Moleculin. “Our ongoing sponsored research at MD Anderson has now resulted in new patented discoveries that clearly demonstrate unusually …

Jan van de Winkel

CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma | Globe Newswire | 12/13/2019

… be a potential treatment option for newly diagnosed patients with multiple myeloma in Europe who are eligible for ASCT,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. The Type II variation application … Oncology (ASCO) Annual Meeting. In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop, manufacture and commercialize daratumumab. About the CASSIOPEIA (MMY3006) study This Phase III study is a randomized, open …

Elizabeth Warren

There’s more upside for biotech even after 24% gains in two months - MarketWatch | 12/12/2019

Biotech has been a great performer since I suggested it as a contrarian play on Oct. 11. In that time, the SPDR S&P Biotech exchange-traded fund XBI, +0.58% is up 24%, and the … makes it less likely, at least for the moment, that Elizabeth Warren’s Medicare for All proposal will become law. “The worst-case scenarios are essentially being looked past,” says Yee. The 38th Annual J.P. Morgan …

Joe Biden

There’s more upside for biotech even after 24% gains in two months - MarketWatch | 12/12/2019

Biotech has been a great performer since I suggested it as a contrarian play on Oct. 11. In that time, the SPDR S&P Biotech exchange-traded fund XBI, +0.58% is up 24%, and the … the bullish dynamic on the political front is that candidate Joe Biden is clearly the front-runner again in the Democratic primaries. This makes it less likely, at least for the moment, that Elizabeth Warren’s …

Paul Hudson

Sanofi to restructure its Onduo, Verily partnership alongside diabetes exit | FierceBiotech | 12/10/2019

… Research, and Bioforum are speeding database builds and automating reporting tasks for data management. Register Now Now, newly installed chief Paul Hudson aims to refocus the company on its strongest products in immunology and vaccines … but will no longer be involved operationally. pic.twitter.com/3FhndN3mb6 — Andy Biotech (@AndyBiotech) December 10, 2019 Regarding Onduo, Hudson said the company “over-invested” in the project in the past. Sanofi will stay on as a …

Johanna Mercier

ASH: Gilead Sciences touts ‘astounding’ Yescarta survival results at 3 years | FiercePharma | 12/8/2019

… least three years ago, nearly half—47%—were still alive at a median follow-up of 39.1 months, the Big Biotech’s Kite unit said at the American Society of Hematology (ASH) annual meeting. Yescarta prolonged … exec Daniel O’Day ; Novartis and Lilly veteran Christi Shaw ; and Johanna Mercier , whom Gilead poached from Bristol-Myers Squibb. It’s also looking beyond Yescarta’s current uses, Emtage said. “The emphasis is not only at increasing …

Bernat Olle

Vedanta Biosciences Awarded $5.8 Million CARB-X Grant to Accelerate Development of VE707 for Multi-Drug Resistant Infections | Business Wire | 12/5/2019

… with the CARB-X team to develop an alternative to antibiotics to help address the burden of MDRO infections,” said Bernat Olle, PhD, chief executive officer of Vedanta Biosciences. “If we could get rid of … difficile infection and inflammatory bowel disease (in collaboration with Janssen Biotech, Inc.), and food allergy, as well as a fourth product candidate expected to enter the clinic in 2019 in patients with advanced or metastatic …

Bernie Sanders

How next week’s universal coverage hearing is shaping up - POLITICO | 12/5/2019

… Pelosi’s drug pricing plan could result in 56 fewer new innovative medicines over the next 10 years from small, emerging biotech companies alone. These companies rely on investment and support from larger biopharmaceutical companies, partnering … available, Jayapal told Alice. Her measure is a companion of Bernie Sanders ‘ Senate legislation . — National Nurses United is pushing for a nurse to testify. The union, which has been a vocal advocate for the House’s …

Bill Gates

Gates Foundation CEO Susan Desmond-Hellmann is stepping down - Business Insider | 12/5/2019

biotech Genentech working on gene therapies for cancer. “Sue brought an incredible set of attributes to the foundation: scientific expertise, tested leadership skills, a passion for building a strong internal culture, and, above all, a dedication to the mission of making the world a healthier, more equal place,” Melinda Gates said in a prepared statement. Desmond-Hellmann’s leadership, Bill Gates said in the statement, helped the foundation launch its research …